View More Recent Stories
-
Outlook Therapeutics (OTLK) Reports Prelim Topline Results of NORSE EIGHT Trial
-
Outlook Therapeutics (OTLK) November 7.5 calls active as share price up 8.7%
-
Outlook Therapeutics (OTLK) Announces Completion of Enrollment in NORSE EIGHT Clinical Trial
-
Outlook Therapeutics, Inc. (OTLK) Tops Q2 EPS by 9c
-
Outlook Therapeutics (OTLK) Announces UK MHRA Marketing Authorization of LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD
